PRE-CLINICAL ANIMAL CORE
PRE-CLINICAL ANIMAL CORE
批准号:
8514330
负责人:
Charles David James
金额:
$16.49万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-05-01 至 2018-08-31
关键词:
Abnormal CellAddressAllograftingAnimal EuthanasiaAnimal ExperimentationAnimal ModelAnimalsApoptoticArchivesBiodistributionBiological AssayBiological MarkersBioluminescenceBlood specimenBrainBrain NeoplasmsCD-ICell CountCell LineCellsCollaborationsDataData QualityDevelopmentEngraftmentEuthanasiaFrequenciesGrantGrowthHumanImmunocompetentImplantIn VitroInstructionIntraperitoneal InjectionsInvestigationInvestigational TherapiesIonizing radiationKi-67 AntigenLengthLifeLuciferasesMalignant - descriptorMethodsModelingMolecularMonitorMusNeurologic SymptomsNude MiceOperative Surgical ProceduresOralOutcomePathologyPatientsPharmaceutical PreparationsPhasePrincipal InvestigatorProceduresProcessProtocols documentationRattusRecordsReproduction sporesResearchResearch PersonnelResectedResourcesRodentRodent ModelSourceSpecimenStaining methodStainsStem cellsSurrogate MarkersSurvival AnalysisTestingTherapeuticTherapeutic EffectTissue and Organ HarvestingTissuesToxic effectTrainingTumor BurdenTumor Cell LineTumor TissueVascularizationXenograft procedureassay developmentbasebioluminescence imagingcaspase-3designexperiencein vivoirradiationmouse modelneoplastic celloptical imagingpre-clinicalpre-clinical therapyresearch studyresponsesubcutaneoustherapeutic targettumortumor growthtumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Because of the translational requirement of SPORE research, it is essential that SPORE investigators have
access to and assistance with animal models for therapeutic hypothesis testing. The UCSF Brain Tumor
SPORE Animal Core addresses this need by using 3 types of rodent intracranial engraftment models, based
on cell of origin: 1) human tumor cells; 2) chemically induced rodent brain tumor cell lines; and 3) tumor cells
derived from genetically modified mouse models. Tumor cells are implanted in the brains of
immunodeficient, and/or immunocompetent hosts, with therapeutic effect determined by bioluminescence
monitoring of tumor growth, animal subject survival analysis, and immunohistochemical analysis of tumor
biologic response indicators, especially proliferation and apoptotic response. In addition, the Core also
conducts studies to assess therapeutic toxicity and biodistribution. These studies typically involve organ and
tissue harvests at pre-determined timepoints, with specimens examined for drug content, and/or indication of
abnormal pathology, and/or abnormal cell counts when blood samples are obtained. Finally, the Core serves
as a source of tumor tissues, resulting from engraftment procedures, for biomarker investigation and assay
development, and for in vitro investigation in instances involving the transfer of viable tissues or cells.
These activities are carried out in association with the following specific aims:
Aim 1: Propagate, analyze (histopathological and molecular), archive, and maintain up-to-date records on all
tumor cell sources and tissues used in support of SPORE animal model research.
Aim 2: Advise and assist all rodent model therapeutics testing, including optical imaging, survival benefit
analysis, toxicity assessment, and molecular analyses of tumors for response to therapy.
Aim 3: In association with the Tissue Core, utilize human xenograft tumor tissues to facilitate the
development of immunohistochemical and FISH assays that can be applied to the investigation of biologic
response indicators, therapeutic targets, and surrogate markers in patient tumors.
Aim 4: Process, and distribute, within and outside of UCSF, xenograft tumor tissues and cell lines, as well as
extracts from each, so as to promote intra- and inter-SPORE collaborations, as well as to support brain
tumor research in general, through utilization of renewable tumor cell resources.
RELEVANCE (See instructions):
Animal model research is a required part of testing investigational therapies prior to their being used to treat
brain tumor patients. As such, and given the translational orientation of SPORE research, there is an
ongoing need of SPORE investigators to perform animal model studies. Such studies are made more
efficient by having specialized staff with animal model research expertise, and who are readily available to
assist in the design and implementation of SPORE animal model research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SLFN5: A Novel Therapeutic Target for Glioblastoma
-
批准号:10240565
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2019
-
负责人:Charles David James
-
依托单位:
SLFN5: A Novel Therapeutic Target for Glioblastoma
-
批准号:10468276
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2019
-
负责人:Charles David James
-
依托单位:
Career Enhancement Program
-
批准号:10224129
-
项目类别:
-
资助金额:$9.71万
-
财政年份:2018
-
负责人:Charles David James
-
依托单位:
Career Enhancement Program
-
批准号:10478884
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2018
-
负责人:Charles David James
-
依托单位:
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy
-
批准号:9134221
-
项目类别:
-
资助金额:$35.65万
-
财政年份:2014
-
负责人:Charles David James
-
依托单位:
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy
-
批准号:8901528
-
项目类别:
-
资助金额:$35.2万
-
财政年份:2014
-
负责人:Charles David James
-
依托单位:
NOVEL APPROACAHES FOR IMPROVING PEDIATRIC BRAFV600E GLIOMA PATIENT OUTCOMES
-
批准号:8514312
-
项目类别:
-
资助金额:$27.15万
-
财政年份:2013
-
负责人:Charles David James
-
依托单位:
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy
-
批准号:8402661
-
项目类别:
-
资助金额:$35.22万
-
财政年份:2012
-
负责人:Charles David James
-
依托单位:
Cdk4/6 Inhibitor Therapy for Glioblastoma Multiforme
-
批准号:8658297
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2012
-
负责人:Charles David James
-
依托单位:
Cdk4/6 Inhibitor Therapy for Glioblastoma Multiforme
-
批准号:8840899
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2012
-
负责人:Charles David James
-
依托单位:
Cdk4/6 Inhibitor Therapy for Glioblastoma Multiforme
-
批准号:8314300
-
项目类别:
-
资助金额:$33.49万
-
财政年份:2012
-
负责人:Charles David James
-
依托单位:
BRAF Mutation in Malignant Astrocytoma Origin, Evolution, and Response to Therapy
-
批准号:8529270
-
项目类别:
-
资助金额:$34.11万
-
财政年份:2012
-
负责人:Charles David James
-
依托单位:
Cdk4/6 Inhibitor Therapy for Glioblastoma Multiforme
-
批准号:8463483
-
项目类别:
-
资助金额:$30.22万
-
财政年份:2012
-
负责人:Charles David James
-
依托单位:
EGRF Targeting of Therapeutic Liposomes for Treating Gliobastoma
-
批准号:7843605
-
项目类别:
-
资助金额:$19.31万
-
财政年份:2009
-
负责人:Charles David James
-
依托单位:
Xenograft Model for Studying Amplified EGFR in GBM
-
批准号:6825627
-
项目类别:
-
资助金额:$30.12万
-
财政年份:2004
-
负责人:Charles David James
-
依托单位:
Xenograft Model for Studying Amplified EGFR in GBM
-
批准号:7228952
-
项目类别:
-
资助金额:$30.37万
-
财政年份:2004
-
负责人:Charles David James
-
依托单位:
Core--Xenograft Facility
-
批准号:6844503
-
项目类别:
-
资助金额:$16.36万
-
财政年份:2004
-
负责人:Charles David James
-
依托单位:
Xenograft Model for Studying Amplified EGFR in GBM
-
批准号:7405313
-
项目类别:
-
资助金额:$30.46万
-
财政年份:2004
-
负责人:Charles David James
-
依托单位:
Xenograft Model for Studying Amplified EGFR in GBM
-
批准号:6928574
-
项目类别:
-
资助金额:$28.93万
-
财政年份:2004
-
负责人:Charles David James
-
依托单位:
Xenograft Model for Studying Amplified EGFR in GBM
-
批准号:7276913
-
项目类别:
-
资助金额:$28.25万
-
财政年份:2004
-
负责人:Charles David James
-
依托单位:
海外基金